Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Assets (2019 - 2025)

Historic Current Assets for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $528.3 million.

  • Kymera Therapeutics' Current Assets fell 710.67% to $528.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $528.3 million, marking a year-over-year decrease of 710.67%. This contributed to the annual value of $510.3 million for FY2024, which is 2589.36% up from last year.
  • Kymera Therapeutics' Current Assets amounted to $528.3 million in Q3 2025, which was down 710.67% from $728.3 million recorded in Q2 2025.
  • Kymera Therapeutics' Current Assets' 5-year high stood at $728.3 million during Q2 2025, with a 5-year trough of $340.8 million in Q1 2021.
  • Its 5-year average for Current Assets is $469.8 million, with a median of $451.3 million in 2021.
  • In the last 5 years, Kymera Therapeutics' Current Assets skyrocketed by 8285.03% in 2021 and then plummeted by 2395.2% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Current Assets (Quarter) stood at $451.3 million in 2021, then decreased by 7.06% to $419.4 million in 2022, then dropped by 3.36% to $405.3 million in 2023, then rose by 25.89% to $510.3 million in 2024, then increased by 3.53% to $528.3 million in 2025.
  • Its Current Assets stands at $528.3 million for Q3 2025, versus $728.3 million for Q2 2025 and $501.0 million for Q1 2025.